While low-dose tamoxifen stimulated the growth of cells overexpressing ZNF703, treatments of tamoxifen-treated MDA-MB-134 and HCC1500 luminal B BC cell lines with (i) ZNF703-siRNA alone significantly reduced survival rates whereas the combination ZNF703-siRNA with the MTOR inhibitor rapamycin enhanced the antitumor effect of tamoxifen [79]. This evidence concerns the gene MTOR and breast cancer.